



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Seishi Kato et al.

Application Serial No: 09/254,760

Filing Date: April 16, 1999

For: *Human Proteins Having Secretory Signal Sequences And DNAs Encoding These Proteins*

Attorney Docket No.: GIN-6704CPUS

Group Art Unit: 1642

Examiner: Wesley Lazar, Ph.D.

Commissioner for Patents  
Office of Petitions  
Box DAC  
Washington, D.C. 20231


Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Office of Petitions, Box DAC, Washington, D.C. 20231 on the date set forth below.

November 2, 2001

Date of Signature and of Mail Deposit

By:

  
Cynthia L. Kanik, Ph.D.  
Reg. No. 37,320  
Attorney for Applicant

PETITION TO REVIVE AN ABANDONED APPLICATION  
PURSUANT TO 37 CFR § 1.137(b)

Dear Sir:

On April 16, 1999, Application Serial No. 09/254,760, claiming priority to PCT/  
Application No. PCT/JP97/03239 (filed 12 September 1997), was filed on behalf of Sagami  
Chemical Research Center. A Notice of Abandonment (Paper No. 7) was issued on May 22,

2000. Applicants respectfully request that the above-identified application be revived under  
37 CFR §1.137(b).

RECEIVED

JAN 18 2002

OFFICE OF PETITIONS  
DEPUTY A/C PATENTS

Under 37 CFR §1.137(b), a Petition to Revive an unintentionally abandoned application must be accompanied by: (1) any required reply, unless it has been previously submitted; (2) a petition fee as set forth in 37 CFR §1.17(m); (3) a statement that the entire delay in filing the required reply from the due date for the reply until the filing of a grantable petition pursuant to this paragraph was unintentional; and (4) any terminal disclaimer under paragraph (c) of this section.

Accordingly, Applicants submit with this Petition to Revive the following:

(1) an Amendment and Response to the Office Communication dated June 2, 2000 (Paper No. 5);

(2) a copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;

(3) a transmittal letter for diskette containing the substitute Sequence Listing;

(4) a paper copy of a substitute Sequence Listing (pages 1 to 28);

(5) a diskette containing a computer readable form (CRF) of the substitute Sequence Listing;

(6) a check for the amount of \$904.00 for the additional independent claims; and

(7) a check for the amount of \$1,280.00 for the petition fee under 37 C.F.R. §1.17(m).

It is respectfully submitted that the entire delay in filing the response until the filing of this petition was unintentional and the present petition is being filed within one year of the date of abandonment. A terminal disclaimer is not required under 37 CFR §1.137(c) because the subject application was filed after June 8, 1995.


herewith. Enclosed is a check which covers the appropriate fee of \$1,280.00 based on large

entity status. Please charge any underpayments or credit any overpayments to our Deposit Account No. 12-0080. A duplicate of this sheet is enclosed.

If Applicants' undersigned attorney can be of assistance in furthering the prosecution of this application, the Examiner is invited to contact her at the telephone number listed below.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Cynthia L. Kanik, Ph.D.  
Registration No. 37,320  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
Tel. (617) 227-7400

Dated: November 2, 2001